About us

Who We Are!

Blueshield Therapeutics is a pioneering biotechnology company committed to revolutionizing depression treatment. Leveraging our proprietary nanobody technology, we aim to address the underlying mechanisms of depression, offering patients a novel, more effective, and safer therapeutic option compared to current treatments. With a team of seasoned professionals experienced in drug discovery and development, we are unwavering in our mission to improve patients’ lives and advance the field of depression treatment.

 

Our Mission

Blueshield Therapeutics’ mission is to innovate safer, more effective therapies for depression using our proprietary nanobody technology, targeting the unmet needs in the current treatment landscape.

 

Market insights

In 2020, the depression drug market was valued at around USD 13.7 billion and projected to reach USD 17.9 billion by 2028, growing at a compound annual growth rate (CAGR) of 2.5%. This market expansion is driven by the escalating prevalence of depression globally, the continued need for effective and well-tolerated treatments, and a growing demand for innovative therapies that can offer differentiated options for patients.

PROBLEM​

Depression

Risk of Suicide:

Depression is a leading cause of Suicide

7% Adults

Over 17 million people in US had sever depression episode.

Economic Consequences

economic burden of depression in the US was estimated to be over $210 billion in 2019

Solution

Our Biologics are the solution

Blueshield Therapeutics' competitive advantage stems from our novel nanobody technology for depression treatment, promising to mitigate the limitations of existing treatments. The gap in the market for biologic depression therapies further amplifies our opportunity.

our Pipeline

News

Founders

Contact us

For more information about Blueshield please contact us today using the form below:

    Collaborators